Overview
Arrowhead Pharmaceuticals develops innovative RNAi-based therapeutics to treat diseases by silencing causative genes. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Pipeline Development Strategy
Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The depth and versatility of our RNAi technologies enable us to address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise druggable by small molecules and biologics.
Leadership
Arrowhead has built an experienced team of leaders that foster a culture of innovation and have a proven ability to advance development programs from idea stage into commercial pharmaceutical products.
Executive Leadership






Department Heads

Vincent Anzalone, CFA
Vice President, Head of Investor Relations

Dave Bormett, MS
Vice President, Quality Assurance

Erik Bush, Ph.D.
Group Vice President, Biology

Peter Carignan, MA, MBA
Vice President, Clinical Operations

Zhi-Ming Ding, M.D., Ph.D.
Vice President, Biology

Christine Esau, Ph.D.
Vice President, Biology

Fred Fleitz, Ph.D.
Group Vice President, Chemistry, Manufacturing & Controls

Leslie Lemke-Boutcher
Vice President, Nonclinical Toxicology

Nadia Meshkova, MBA
Vice President, Treasurer

Tao Pei, Ph.D.
Group Vice President, Chemistry

Matt Pulisic, MBA
Vice President of Finance

Thomas Schluep, Sc.D.
Vice President, Program Management

Jack Shi, Ph.D.
Vice President, Clinical Pharmacology

Randy Steiner, DPA, MS
Vice President, Regulatory Affairs

Aaron Tan, MBT
Head of Tax
